Now that the complete sequences for human chromosome 21 and the orthologous mouse genomic regions are known, reasonably complete, conserved, protein-coding gene catalogues are also available. The central issue now facing Down's syndrome researchers is the correlation of increased expression of specific, normal, chromosome 21 genes with the development of specific deficits in learning and memory. Because of the number of candidate genes involved, the number of alternative splice variants of individual genes and the number of pathways in which these genes function, a pathway analysis approach will be critical to success. Here, three examples, both gene specific and pathway related, that would benefit from pathway analysis are discussed: (1) the potential roles of eight chromosome 21 proteins in RNA processing pathways; (2) the chromosome 21 protein intersectin 1 and its domain composition, alternative splicing, protein interactions and functions; and (3) the interactions of ten chromosome 21 proteins with components of the mitogen-activated protein kinase and the calcineurin signalling pathways. A productive approach to developing gene-phenotype correlations in Down's syndrome will make use of known and predicted functions and interactions of chromosome 21 genes to predict pathways that may be perturbed by their increased levels of expression. Investigations may then be targeted in animal models to specific interactions, intermediate steps or end-points of such pathways and the downstreamperhaps amplified -consequences of gene dosage directly assessed. Once pathway perturbations have been identified, the potential for rational design of therapeutics becomes practical.
INTRODUCTION
With an incidence of approximately one in 700 live births, Down's syndrome (DS) is the most common genetic cause of mental retardation. 1 DS, or trisomy 21, is caused by an extra, third, copy of all or part of human chromosome 21 and the consequent overexpression of genes encoded within it. The complete phenotype of DS is complex and variable in severity; most organs and organ systems are involved, resulting in heart defects, immune system deficiencies, hypotonia, skeletal abnormalities and an increased risk of leukaemia. 2 The mental retardation, manifested in specific cognitive and behavioural deficits, is the primary deficit common to all persons with DS and, thus, may be the most critical issue for quality of life for the general DS population. The average IQ is 50 and ranges from severely retarded to low normal. 3 This does not reflect a generalised dysfunction, but rather involves impairment of specific learning and memory tasks requiring specific regions of the brain. For example, children aged 18-30 months with DS were successful in the learning phase of three hippocampal-specific tasks, but, in the memory phase, they were successful in only two of the three tasks. 4 Pennington et al. 5 studied older children with DS and specific dysfunction was demonstrated in: (1) hippocampal tasks that did not involve the parahippocampal or the pirihinal region and (2) in prefrontal cortex tasks, affecting verbal but not non-verbal tasks. Specific neuroanatomical features of the DS brain include decreased sizes of the hippocampus, pre-frontal cortex and cerebellum, a decrease in dendritic arborisation, premature degeneration of functional markers in the cholinergic neurones of the basal forebrain and development of plaques and tangles characteristic of Alzheimer's disease. 4, 6 Together, these observations show the specificities in DS-associated neuroabnormalities. The challenge now is to link specific genes and the pathways in which they function to these features.
MOLECULAR HYPOTHESIS
The rational basic assumptions guiding DS research are that: (1) individual chromosome 21 genes will show gene dosage effects that increase expression by 50 per cent at the RNA and the protein levels; (2) at least some of these increases will result in perturbations of the pathways and cellular processes in which these genes function; and (3) these perturbations, possibly additively, will result in the neurodevelopmental and cognitive abnormalities that characterise the mental retardation of DS. These assumptions emphasise that, in comparison with mental retardation due to single gene defects, DS presents some unique complexities: (1) there is no abnormal or absent gene function, there is merely a modestly increased level of normal gene activity; and (2) there is a large number (.300) of candidate genes and, consequently, multiple pathways are likely to be involved.
Comparative annotation of the complete sequences of chromosome 21 and the orthologous regions of mouse chromosomes 16, 17 and 10 has provided a reasonably complete catalogue of the protein-coding genes that comprise the candidate gene set. Recent studies identified 364 genes and gene models on human chromosome 21 and 291 in the orthologous mouse genomic regions. 7 There are 170 highly conserved, clearly orthologous gene pairs, plus 83 less wellconserved, possible orthologues. For 140 of the highly conserved genes, there is some functional annotation that can be used to inform predictions of their relevance to mental retardation. 8 Logically, there is no simple, reliable strategy for choosing any individual gene as the best candidate. Our biological knowledge of even the best-studied gene is incomplete and undoubtedly underestimates the diversity of protein isoforms and expression patterns, and the complexity of protein interactions and functions. As discussed below in several examples, many chromosome 21 genes have been shown to interact mutually or to function within the same pathways. Studying effects of overexpression of a single gene will miss the synergistic effects of the multigene interactions, and will perhaps fail to produce a relevant phenotype or to recapitulate the strength of the phenotype.
Increased expression due to gene dosage in DS received experimental support from the earliest measurements carried out on genes such as superoxide dismutase (SOD), cystathionine â-synthetase, phosphofructokinase and phosphoribosylglycinamide synthetase, among others. 9 Measurements were made in DS cells at the level of RNA, protein and, in some cases, protein activity, and were subsequently confirmed, where possible, in the segmental trisomy mouse model of DS, Ts65Dn.
10,11 Some recent human data, though, have failed to support gene dosage-related expression increases [12] [13] [14] [15] and some of these data conflict with mouse data on the same genes. 8 Conflicting results may arise from the use of human versus mouse, tissue versus cell lines or foetal versus adult tissues, and they may be due to differential regulatory effects of other chromosome 21 genes, or to artefacts, or to the challenges of obtaining quality tissues and measuring small differences in expression levels. Regardless, building hypotheses relating chromosome 21 genes to pathway perturbations and to phenotypic consequences certainly requires careful initial verification of increased expression of the candidate chromosome 21 genes.
DS presents particular challenges in large-scale analyses because of the small Challenges in DS include the large number of candidate genes and the modest increases in their expression levels initiating perturbations, the gene dosagedefined increases of 50 per cent in expression level. The authors suggest that a pathway analysis approach will make DS a tractable problem, one amenable to the development of therapeutics. Correlating sets of genes with specific pathways will allow a directed search for pathway perturbations that can then be linked to neuroanatomical or cognitive abnormalities, and suggest effective design of pathway-targeted therapeutics. Progress in pathway associations obtained by compiling information from databases and the literature will be discussed. Because of the number of pathways currently implicated, these data suggest that, just as overexpression of single genes will not account for the DS cognitive phenotype, it is most likely that neither will perturbations of single pathways. 17 Adenosine deaminase that acts on RNA 2 (ADAR2) acts on specific premRNAs to produce inosines at one or a few specific sites. 18 Such 'editing' alters the protein sequence and functional properties of known substrates, which include neurologically relevant glutamate and serotonin receptors and a potassium channel. Because it requires a doublestranded RNA structure typically formed between the site to be deaminated and an adjacent intronic sequence, ADAR2 is postulated to act before or concomitantly with splicing. Recently, Raitskin et al. 19 demonstrated that ADAR2 could be detected in complexes from HeLa cells that also contained SR proteins. In addition, if editing is blocked, splicing is inhibited and quantities of mature message are reduced. 20 Dual specificity tyrosine-regulated protein kinase 1 (DYRKIA), a serinethreonine protein kinase, has been shown to localise to the nuclear speckles that represent the splicing compartment. 21 In
RNA PROCESSING PATHWAY
Multiple pathways affecting cognition are likely to be impacted in DS Diverse data suggest that there may be subtle defects in RNA processing in DS 22 have presented data that suggest that DRYK1A substrates include the SR proteins SRp75 and cyclin L2, and possibly the splicing factors SFrS5, SF3B1 and SWAP2. APP, the Alzheimer's disease amyloid precursor protein, is unique among genes discussed here in that it is subject to proteolytic processing. 23, 24 This produces several different fragments, among which is the neurotoxic Aâ 1-42 that accumulates in the plaques typifying Alzheimer's disease and a carboxy-terminal, 99-amino acid fragment C99. A phosphorylated protein, which is most likely this latter fragment, has recently been shown to localise with splicing factors in the splicing factor compartment. 25 Large-scale proteomic approaches have also provided insight. Rappsilber et al. 26 isolated spliceosome complexes from HeLa cells, directly digested them with trypsin and analysed the peptides by mass spectrometry. Included among the 351 proteins identified were all known spliceosome components plus a number of the novel proteins of unknown function. Included in the latter group were two chromosome 21 proteins, C21orf66 and C21orf70, the first of which was confirmed in a similar analysis.
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PCBP3 is characterised as a poly-C binding protein, and contains three hnRNP K homology (KH) domains. 28 Although the function of PCBP3 has not been demonstrated, family members have been shown to function in posttranscriptional control. Interestingly, the organisation of the PCBP3 KH domains, two near the amino terminus and the third near the carboxy terminus, is the same as that in the Nova-1 protein, and the sequences of the KH domains are $60 per cent similar to those of Nova-1. Nova-1 is a neurone-specific protein, which has been shown to be involved in alternative splicing of a glycine and a GABA receptor and other neuronally relevant mRNAs; 29 knockout of Nova-1 function affects these splicing patterns and has severe neurological consequences. 30 Questions remain regarding the associations of these proteins with splicing -for example are some or all of these proteins ever found in the same complex, are there cell-type or tissue variations or gene-specific associations and, most importantly, does overexpression perturb splicing pathways either in a general or a gene-specific manner? There are many examples of neurological abnormalities resulting from either general or genespecific splicing defects. 31 It is reasonable to speculate that one molecular feature contributing to the DS phenotype could be perturbation of constitutive or alternative splicing patterns. It will be challenging to devise effective strategies to investigate this possibility.
INTERSECTIN 1 PROTEIN FUNCTIONS AND INTERACTIONS
Intersectin 1 (ITSN1) is a 41-exon, multidomain protein that functions in clathrin-mediated endocytosis and mitogen-activated protein kinase (MAPK) signalling pathways.
32 ITSN1 occurs in two major isoforms -the neuronespecific long form, ITSN1-L, and the more ubiquitously expressed short form, ITSN1-S, which lacks the three C-terminal domains, RhoGEF, PH and C2. Predicting pathway perturbations due to overexpression of ITSN1 is complicated by its numerous protein interactions, multiple domain-associated functions and additional domain-related alternative splicing. Some of this information is summarised in Figure 1 .
At the amino terminal, yeast twohybrid experiments showed that the two epidermal growth factor protein substrate 15 Eps15 homology (EH) domains bind Epsin1 and 2, both required for clathrinmediated endocytosis, 34 and Stonin2, a homologue of the Drosophila StonedB, a neurological mutant and component of the endocytic machinery. 35 The EH domains also bind novel proteins Ibp1 and 2 that encode consensus clathrin-binding sequences, and the nucleoporin homologue and REV-associated binding/ Rev-interacting protein. 36 The
Perturbations in RNA processing may be gene and/or cell type specific characterisation of these interacting proteins as accessory factors for clathrinmediated endocytosis 37 suggests that ITSN1 functions as a scaffolding protein facilitating endocytosis in nerve termini. Downstream of the EH domains, the KLERQ putative coiled-coil region has been shown to bind Eps15, 34 a protein that is enriched in synapses and localised at clathrin-coated pits 37 and SNAP25 38 , a membrane-bound protein involved in synaptic vesicle exocytosis in nerve termini.
Diverse approaches have identified protein interactions and their differing affinities for the five SH3 domains. In yeast two-hybrid experiments, Sengar et al. 34 showed that a construct containing only the five SH3 domains interacted with dynamin. In pull-down experiments and far Western blot analysis from rat brain, Yamabhai et al. 36 demonstrated that SH3A binds synaptojanin (SYNJ1) and dynamin strongly, SH3C or SH3E less strongly and SH3B and SH3D not at all. Okamoto et al. 38 also demonstrated binding of dynamin but only to SH3C and the combination SH3D,E. The failure of dynamin to bind to the SH3A,B construct correlates with the use of a splice variant containing exon 20 that inserts five amino acids into the SH3A domain. In rat brain, the SH3A domain competes with Grb2 for binding to sonof-sevenless (Sos), a guanine nucleotide exchange factor for Ras; 39 Sos also binds equally well to SH3C and SH3E domains. 40 Jenna et al. 41 demonstrated The functional associations of ITSN1 are also diverse. Adams et al. 43 showed that overexpression in HEK293 cells of a construct containing only the EH domains activated the Elk transcription factor; the activation was attenuated when a complete ITSN1-S construct was used. Sengar et al. 34 showed that overexpression in cos7 cells of ITSN1-S blocked endocytosis as monitored by transferrin uptake. Tong et al. 39, 44 showed that overexpression of an SH3 domain construct blocks activation of Ras, possibly due to the competition of ITSN1 binding to Sos, thus preventing its interaction with Grb2 and proximity to Ras. In contrast, Mohney et al. 40 demonstrated that overexpression of the complete ITSN-S activated Ras; they also showed that activation of Elk transcription occurred through activation of Jnk. In ITSN1-L, the RhoGEF (or double homology, DH) domain has guanine nucleotide exchange activity specific for Cdc42, and ITSN stimulation of Cdc42 accelerates actin assembly; 42 binding of N-WASP to the SH3 domains enhances this activity. This activity might be further enhanced by the binding of CdGAP, because its GTPase activity towards Cdc42 is then inhibited. Competition between the binding of these and other proteins to the SH3 domains may serve to regulate the RhoGEF activity or to couple it to endocytosis. 45 The protein interactions and functions of ITSN are likely to be modulated by documented alternative splicing events. These reduce the spacing between the EH domains from 105 to 68 amino acids, insert five amino acids into the SH3A domain (which affects dynamin binding, see above), delete the SH3C domain and change the sequence of the RhoGEF domain. 33, 38, 46 While some of these events are rare, as monitored at the RNA level, and some have yet to be verified as translated products, they show neurologically-relevant developmental and tissue-specific patterns.
The 48 this results in activation of dendritic spine morphogenesis, which is anomalous in DS. Increased levels of expression of the two major ITSN1 protein isoforms have been verified in brains of the DS mouse model Ts65Dn, 8 and it is reasonable to propose that this increased expression will have multiple consequences at the molecular level, as Effects of increased expression of ITSN in cell culture need to be corroborated in mouse models of DS well as macroscopic phenotypic consequences, both in mouse models and in DS, which may include dendritic spine morphology and endocytosis. The complexity of ITSN functions, and the difficulty of simultaneously regulating all of them, argues for a pathway analysis approach with the possibility of pathway regulation.
MAPK AND CALCIUMÀCALCINEURIN PATHWAYS
MAPK and calcineurin pathways are of compelling interest to cognition in DS because of the following observations: (1) genetic and pharmacological manipulation of the flux through MAPK pathways results in impaired learning of hippocampal-based tasks; 49 (Figure 2) . MAPK pathways are activated by the binding of NGF, and other stimuli, to their receptors. Initial MAPK pathway components are the trio of kinases that effect a cascade of activations through phosphorylation of their respective targets. These trios include Raf-Mek1/2-Erk1/2 and Mekk1-Mkk4/7-Jnk. 52 Correct levels of both Ras and Erk1/2 activation are required for hippocampalbased tasks such as spatial learning and context fear conditioning. Zhao et al. 53 and Blum et al. 54 demonstrated increased phosphorylation of Erk1/2 in the hippocampus of normal rats, after training in the spatial Morris water maze. Pharmacological inhibition of ERK1/2 phosphorylation blocked formation of the spatial long-term memory. Erk1/2 activation was also observed in the hippocampus-dependent task, in contextdependent fear conditioning 55 and in the insular cortex after conditioned taste aversion. Genetic manipulation of MAPK signalling also inhibits spatial learning: K-Ras null heterozygote mice (showing decreased Ras activation levels) are impaired in the hidden platform version of the Morris water maze 56 and mouse models carrying mutations in the neurofibromatosis 1 gene, which result in hyperactivated Ras, 57 also show deficits in hippocampal-based tasks including spatial learning and context discrimination. 58 Data on cognitive function in the DS mouse model, the segmental trisomy Ts65Dn, 10, 11, 59 support the potential involvement of the MAPK pathway in DS. These mice show impairments in spatial learning in the Morris water maze and the radial maze. [60] [61] [62] While impairments in these mazes are not necessarily hippocampal derived, there is definitive evidence for hippocampal deficits in the Ts65Dn model: these mice develop deficits in hippocampaldependent context discrimination 63, 64 that correlate with observable loss of cholinergic markers 65 and they are severely impaired in conditioned taste aversion (L. Crnic, unpublished data). Hippocampal Erk1/2 activation is also involved in long-term potentiation, 66 which has been reported to be impaired in the Ts65Dn mouse. 67, 68 Calcineurin (CaN), a Ca 2þ / calmodulin-dependent serine-threonine protein phosphatase, has been shown to function in T-cell activation, muscle hypertrophy and, especially relevant to DS, synaptic plasticity and memory development. 69 CaN activity has been manipulated by genetic and pharmacological methods that variously produced increases in activity in specific brain regions, decreases at specific adult time points and decreases that persisted throughout development and adulthood. [70] [71] [72] [73] [74] Consistent with the variety of methods used, results were variable, but, in considering DS, the most relevant experimental paradigm (a knockout of a CaN subunit 74 ) affected hippocampal-based learning, including the Morris water maze. Protein targets of calcineurin include dynamin, amphiphysins 1 and 2 and the chromosome 21-encoded synaptojanin. 75 All function in endocytosis in nerve termini and are activated by CaN dephosphorylation. Perturbations of calcineurin activity may, therefore, impact endocytosis. 50 CaN has also been shown to affect Jnk activation strongly and Erk1/ 2 weakly. 76 Table 2 lists chromosome 21 proteins that directly or indirectly impact, or are impacted by, components of the MAPK and/or the Ca 2þ -CaN signalling pathways. An abbreviated schematic of these pathways and the interactions of chromosome 21 genes are shown in Figure 2 and briefly described here. ITSN1 and SYNJ1 a phosphoinositol phosphatase function in endocytosis in nerve termini by their interactions with dynamin and other clathrin accessory proteins; 37 DYRK1A, a protein kinase discussed above in RNA processing, affects endocytosis through regulation by phosphorylation of one of its substrates, dynamin. 77 As discussed above, ITSN is documented as participating in activation of the MAPK components, Ras and Jnk. 40 The chromosome 21-encoded protein, TIAM1, has been shown to be a RhoGEF with specificity for Rac, 78 and, therefore, also directly affects MAPK Functional data on several chromosome 21 proteins predict their impact on MAP kinase signalling Transcription factor; regulates APP; target of MAPK (Erk1/2) GABPA Transcription factor; target of MAPK (Erk1/2) RUNX1 Transcription factor; target of MAPK (Erk1/2) RIP140 Transcription co-activator; targets include oestrogen, glucocorticoid receptors through Rac, to Jnk and to Ras activation. Together, these data predict perturbations of the MAPK pathway in DS. DS critical region 1 (DSCR1), also known as calcipressin 1 and MCIP1 is of critical importance to the CaN pathway 79 and is one point of connection between it and the MAPK pathway. DSCR1 directly inhibits CaN and, therefore, indirectly affects CaN substrates, which include dynamin and SYNJ1. 75 Overexpression of the DSCR1 homologue (nebula) in Drosophila resulted in impaired learning.
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DSCR1 is also activated by hydrogen peroxide (H 2 O 2 ), which is produced by another chromosome 21 protein, SOD1 (superoxide dismutase); levels of H 2 O 2 are increased in DS and, consistent with this increase, DSCR1 expression is elevated 2-3-fold in DS brain, higher than the expected 1.5-fold from gene dosage. 81 The chromosome 21 protein, Purkinjie cell protein 4 (PCP4), is a short, 61-amino acid protein that binds calmodulin. In vitro studies show that PCP4 inhibits the activity of the calmodulin-dependent enzyme neuronal nitric oxide synthase. 82 Because CaN is also calmodulin dependent, overexpression of PCP4 may similarly contribute to inhibition of CaN activity in specific hippocampal regions. Together, these data predict perturbation of CaN activity in DS and, therefore, inhibition of endocytosis and of MAPK at Jnk and Erk1/2 activation, although negative feedback complicates predictions: DSCR1 is inactivated by dephosphorylation by CaN. 83 APP is mutated in some forms of familial Alzheimer's disease. APP is regulated by alternative splicing and by processing by AE, â and ª proteases. 23, 24 Multiple products include soluble secreted amino-terminal forms of APP, internal short peptides, of which Aâ 1-42 is the neurotoxic form found in AD plaques, and cytoplasmic C-terminal fragments. APP is another point of connection between MAPK and CaN: (1) and (5) chronic elevation of Aâ activates Erk1/2 through the AE7 nicotinic acetylcholine receptor in an age-related pattern. 87 APP expression levels in DS are affected by gene dosage; they may be affected further because the chromosome 21-encoded transcription factor ETS2 has been documented to activate APP transcription. 88 Furthermore, overexpression of the chromosome 21-encoded small ubiquitin-like protein (SUM03), also known as SMT3A, has been shown to decrease production of the neurotoxic Aâ fragment. 89 Included in Figure 2 are some chromosome 21-encoded transcription factors that are targets of MAPK: the ETS2 oncogene, the GA-binding protein, GABPA, and the runt-domain protein, RUNX1. 90, 91 The receptor-interacting protein 140 (RIP140), also chromosome 21 encoded, is included because it modulates the transcription effects of the oestrogen receptor (ER). 92 Overexpression of these may add downstream effects to the perturbations of MAPK.
All together, Figure 2 shows ten chromosome 21 proteins predicted to affect MAPK and CaN, plus three others relevant to the targets of MAPK. Effects of each gene were determined individually and rarely in the whole organism or within the complete genomic context. Because of the complexity of the positive and negative effects, and the limitations of current knowledge, it is not possible by visual inspection of Figure 2 to predict the outcome of overexpression of chromosome 21 genes. To test the hypothesis of perturbed MAPK flux in the Ts65Dn mice, quantitative Western blot analysis was used. Figure 3 shows that phosphorylation of both Erk1 and Erk2 is altered in the cerebrums and in the hippocampi of Ts65Dn mice; however, there is an age dependence to Calcineurin activity is inhibited by the chromosome 21 protein DSCR1, and possibly also by overexpression of SOD1 and PCP4 Activation levels of MAPK components, ERK 1/2, are abnormal in Ts65Dn mouse model brains the direction of the change: young mice (,2 months) show an increase in activation, mice of $5 months show a significant decrease and old mice ($17 months) again show an increase. The change at $5 months is of particular interest because this is an age when it is known that significant changes are occurring in the brain 65 -behavioural deficits are developing and loss of cholinergic functional markers is beginning. Note that increased expression of chromosome 21-encoded proteins and/or orthologues of ITSN, SYNJ1, APP and DSCR1 has been verified in trisomy. 8, 81 A decrease in calcineurin activity of $30 per cent has been demonstrated in DS foetal brain relative to normal controls 80 and there is preliminary evidence of equally decreased calcineurin activity in aged ($24 months) Ts65Dn cerebrums (data not shown). Although the alterations in Erk1/2 activation and CaN activity are modest, $30-50 per cent, they are as dramatic as the initiating perturbations generated by gene dosage.
DISCUSSION
One goal of DS research is the development of therapeutics to prevent or ameliorate the cognitive deficits. The complexity and the subtlety of the problem -a modest increase in expression of .300 genes starting in development -makes this a challenge. Nevertheless, the approach of pathway analysis offers both intriguing and practical possibilities. Several points in the MAPK pathway and CaN itself are targets of known drugs that, in appropriate concentrations, can moderate flux through the pathways; 49, 69 presumably this drug repertoire can be expanded. An added advantage is that, with the exception of RIP140, the Ts65Dn mouse model of DS is trisomic for orthologues of all chromosome 21-encoded proteins indicated in Figure  2 . 7, 8 Thus, it provides an excellent model for testing therapeutics. Lastly, there are well-established behavioural tests that enable monitoring of the effects of drug intervention using that most complex and relevant of read-outs -learning and memory. Pathway analysis, particularly in the whole organism, has the added advantage that it allows for the monitoring effects of multiple, in this case ten, chromosome 21 genes, each in its correct genomic context with the full repertoire of splice variants. Thus, the complex details of cell type and developmental specificities of protein interactions, processing and functions of ITSN, APP and the other These and other pathway analyses may provide information to encourage development of therapeutics Figure 3 : Perturbation of mitogen activated protein kinase (MAPK) in brains from the Ts65Dn mouse model of DS. Protein lysates were prepared in the presence of protease and phosphatase inhibitors from cerebrums or hippocampi of segmental trisomy Ts65Dn mice and normal littermate controls of the ages indicated. For the 1.7 month mice, three pairs were examined; for the 5.1 month and 16.9 month mice, seven pairs each were examined. Proteins were resolved on denaturing polyacrylaminde gels and electrophoretically transferred to nylon membranes using standard protocols. Antibodies to the phosphorylated forms of Erk1/2 and tubulin were used simultaneously in alkaline phosphatase detection with the CDP-Star system (Applied Biosystems). Signals were detected and quantitated using the DIANA III chemiluminescence imaging and analysis system (Raytest, Germany). pErk1/2 signals were normalised to those for tubulin. Representative Western blots with pErk1/2 for each age group are shown at the left; two pairs of tubulin signals are shown as an example of typical results. C, control, wild-type mice; T, trisomic, Ts65Dn mice. Quantitation of pErk1 and pErk2 levels from three replicates for each pair of mice in all three age groups are shown in the histograms; all differences are significant with p,0.01 using the Students t-test (Prizm software). Levels for both pErk1 and pErk2 are increased relative to controls in the 1.7 and the 16.9 month mice, while they are decreased in the 5.1 month mice genes do not need to be known if the cumulative downstream effects of overexpression can be identified and moderated.
MAPK and CaN are not the only pathways predicted to be impacted in DS. Current functional information shows that multiple chromosome 21 genes are likely to affect protein processing (ubiquitination, sumoylation, proteolytic cleavage), mitochondrial function and reactive oxygen species production, one carbon metabolism and cell adhesion. 8 Of these, mitochondrial function and reactive oxygen species are already compelling targets in the study of neurodegeneration, 93, 94 and one carbon metabolism may provide links to the cholinergic degeneration phenotype. 95 In these cases, not all relevant chromosome 21 genes are trisomic in the Ts65Dn mouse. DS-relevant analysis of most these pathways will require the construction of complex mouse models if all interacting genes are to be trisomic; this is a critical issue if DS is to be reliably modelled.
Additional pathways are likely to be implicated as the understanding of protein function develops. For this, it will be necessary to monitor the literature for reports of functional analyses of individual chromosome 21 genes and their orthologues in other species. Also useful will be the results of large-scale proteomic analyses, such as those being reported as complete interaction maps for yeast and Caenorhabditis elegans, large-scale mutagenesis studies in zebrafish and mouse and even operon composition in C. elegans.
96-100 Not all such data will be applicable, but all will need to be considered in predicting pathway associations in DS. Once the involvement of a specific pathway is predicted, it can be tested in the Ts65Dn or other mouse model and assigned a priority for further study.
In summary, with the completion of the human and model organism genome projects and the development of largescale RNA and proteomics tools, new possibilities for DS research are available. Additional pathways relevant to DS will likely be identified as functional data accumulate on chromosome 21 proteins
